Investigation of Toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: a bronchoalveolar lavage study

Table 2 Demographic and lung function characteristics of patient groups.

Characteristics	Controls	IPF	CTD-IP	SARC	P value
Number	11	16	16	14	-
Age*	58.44 ± 3.49	67.27 ± 1.62	64.23 ± 4.29	47.42 ± 4.65	p2:0.001 p3:0.04 p4:0.01
Gender: (male/female)**	8/3	12/4	3/13	5/9	p1: < 10^-4 p2:0.02 p5:0.002 p6:0.04
Nonsmokers**	3	6	14	5	p1: 0.00 p4:0.004 p5:0.001
Smokers**	7	1	1	4	p3:0.001 p5:0.001
Ex-smokers**	1	9	1	5	p1:0.003 p3:0.02
FEV1*	85.11 ± 7.89	82.44 ± 6.15	86.93 ± 6.37	89.83 ± 6.96	NS
FVC*	91.56 ± 7.46	76.06 ± 5.23	81.07 ± 5.65	91.75 ± 5.97	p2:0.06
FEV1/FVC*	74.56 ± 4.48	85.14 ± 2.76	85.36 ± 2.57	81.36 ± 2.63	p5:0.057
DLCO*	76.22 ± 7.72	54.19 ± 7.18	60.15 ± 5.12	91.3 ± 8.06	p2:0.002 p3:0.05 p4:0.005
KCO*	86.22 ± 8.14	87.63 ± 6.44	79 ± 6.92	108.9 ± 5.91	p2:0.02 p4:0.003 p6:0.04

Values are expressed as means ± SEM (standard error of the mean).
*t-test; P < 0.05 is considered statistically significant.
**χ² test; P < 0.05 is considered statistically significant.
NS, not significant.
Abbreviations: FEV1: forced expiratory volume in one second, FVC: forced vital capacity, TLC: total lung capacity, DL_CO, diffusing capacity for carbon monoxide, KCO: DLCO per unit lung volume. p1: P value between IPF and CTD-IPs, p2: P value between IPF and sarcoidosis, p3: P value between IPF and control, p4: P value between CTD-IP and sarcoidosis, p5: P value between CTD-IP and control, p6: P value between sarcoidosis and control.

ISSN: 1755-1536